CBS 2019
CBSMD教育中心
中 文

Bifurcation Stenting

Abstract

Recommended Article

Double-Kissing Culotte Technique for Coronary Bifurcation Stenting - Technical evaluation and comparison with conventional double stenting techniques Percutaneous Coronary Intervention For Bifurcation Coronary Lesions.The 15th Consensus Document from the European Bifurcation Club ‘Small bifurcation?’ CT myocardial mass volume measurements change therapeutic strategy in coronary artery disease Influence of the sequence of proximal optimisation technique and side branch dilation for the opening of jailed struts after coronary bifurcation stenting Comparison of intravascular ultrasound-guided with angiography-guided double kissing crush stenting for patients with complex coronary bifurcation lesions: rationale and design of a prospective, randomized and multicenter DKCRUSH VIII trial A randomized trial of bifurcation stenting technique in chronic total occlusions percutaneous coronary intervention Streamlined reverse wire technique for the treatment of complex bifurcated lesions European Bifurcation Club White Paper on Stenting Techniques for Patients With Bifurcated Coronary Artery Lesions

Original Research2021 Jul 7.

JOURNAL:Eur J Heart Fail. Article Link

Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction

K-P Kresoja, K-P Rommel, R Wachter et al. Keywords: HFpEF; HFpEF; biomarker; fibrosis; inflammation; obesity; proteomics

ABSTRACT

AIMS -  Recent evidence points towards a distinct obese phenotype among patients with heart failure with preserved ejection fraction (HFpEF). We aimed to identify differentially expressed circulating biomarkers in obese HFpEF patients and link them to disease severity and outcomes.

 

METHODS AND RESULTS -  From the LIFE-Heart study, 999 patients with HFpEF and 999 patients without heart failure (no-HF) were selected and 92 circulating serum biomarkers were measured using a proximity extension assay. Elevation of identified biomarkers was validated in 220 patients from the Aldo-DHF trial with diagnosed HFpEF. HFpEF patients were older and had more comorbidities including coronary artery disease and type 2 diabetes as compared to no-HF patients (p<0.05 for all). After adjusting for covariates, Adrenomedullin (ADM), Galectin-9 (Gal-9), Thrombospondin-2 (THBS-2), CD4, and TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) were significantly higher in obese HFpEF (BMI30 kg/m2 , n=464) patients as compared to lean HFpEF (BMI<30 kg/m2 , n=535) and obese no-HF patients (BMI30 kg/m2 , n=387) (p<0.001 for both), those findings were verified in the Aldo-DHF validation cohort (p<0.001). Except for CD4 these proteins were associated with increased estimates of left atrial pressure in a linear fashion. Importantly, ADM, TRAIL-R2 and CD4 were associated with increased mortality in obese HFpEF patients after adjusting for covariates.

 

CONCLUSION -  Obese HFpEF patients exhibit higher circulating biomarkers of volume expansion (ADM), myocardial fibrosis (THBS-2) and systemic inflammation (Gal-9, CD4) compared to obese non-HFpEF or lean HFpEF. These findings support the clinical definition of a distinct obese HFpEF phenotype and might merit further investigation. This article is protected by copyright. All rights reserved.